These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1021 related items for PubMed ID: 9432985

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D, Dutoit V, Liénard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P.
    Cancer Res; 2000 Aug 15; 60(16):4499-506. PubMed ID: 10969798
    [Abstract] [Full Text] [Related]

  • 4. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
    Chen JL, Dunbar PR, Gileadi U, Jäger E, Gnjatic S, Nagata Y, Stockert E, Panicali DL, Chen YT, Knuth A, Old LJ, Cerundolo V.
    J Immunol; 2000 Jul 15; 165(2):948-55. PubMed ID: 10878370
    [Abstract] [Full Text] [Related]

  • 5. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution.
    Bownds S, Tong-On P, Rosenberg SA, Parkhurst M.
    J Immunother; 2001 Jul 15; 24(1):1-9. PubMed ID: 11211143
    [Abstract] [Full Text] [Related]

  • 6. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E, Karbach J, Gnjatic S, Jäger D, Maeurer M, Atmaca A, Arand M, Skipper J, Stockert E, Chen YT, Old LJ, Knuth A.
    Cancer Immun; 2002 Sep 19; 2():12. PubMed ID: 12747757
    [Abstract] [Full Text] [Related]

  • 7. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
    Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY, Tai TY, Cohen CJ, Old LJ, Pfreundschuh M, Reiter Y, Hoogenboom HR, Renner C.
    Eur J Immunol; 2004 Oct 19; 34(10):2919-29. PubMed ID: 15368308
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
    Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski HR, Heberer M, Spagnoli GC.
    Int J Cancer; 2007 Jan 15; 120(2):337-43. PubMed ID: 17066423
    [Abstract] [Full Text] [Related]

  • 10. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
    Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM.
    J Immunol; 2005 Feb 01; 174(3):1751-9. PubMed ID: 15661941
    [Abstract] [Full Text] [Related]

  • 11. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
    Yamaguchi H, Tanaka F, Ohta M, Inoue H, Mori M.
    Clin Cancer Res; 2004 Feb 01; 10(3):890-6. PubMed ID: 14871964
    [Abstract] [Full Text] [Related]

  • 12. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method.
    Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K.
    Eur J Immunol; 2002 Mar 01; 32(3):826-36. PubMed ID: 11870627
    [Abstract] [Full Text] [Related]

  • 13. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.
    van Elsas A, van der Burg SH, van der Minne CE, Borghi M, Mourer JS, Melief CJ, Schrier PI.
    Eur J Immunol; 1996 Aug 01; 26(8):1683-9. PubMed ID: 8765006
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.
    Jäger E, Gnjatic S, Nagata Y, Stockert E, Jäger D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A.
    Proc Natl Acad Sci U S A; 2000 Oct 24; 97(22):12198-203. PubMed ID: 11027314
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
    Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF.
    Proc Natl Acad Sci U S A; 2001 Mar 27; 98(7):3964-9. PubMed ID: 11259659
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.
    Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, Rosenberg SA.
    J Immunother; 2004 Mar 27; 27(6):472-7. PubMed ID: 15534491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.